ALPAT.PA Plant Advanced Technologies SA

Healthcare Biotechnology Euronext Paris
4.00 EUR
Close of Nov 8, 2026
3.20 8.86
Market cap
EUR 4.56M
P/E
6.7x
P/B
0.46x
ROE
-2.1%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALPAT.PA undervalued?

Graham number
Price4.00
Graham value10.83
Discount63.1%

ALPAT.PA trades 63.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Plant Advanced Technologies SA fundamental analysis

3 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-4.87%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-3.29%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 1/2

The stock maintains a fair debt to equity ratio (63%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Net Profit Growth 0/2

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

Assets Growth 2/2

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

Graham Number 0/1

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

Dividend Growth 0/2

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Dividend 0/2

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Buffet Intrinsic Value 0/1

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Plant Advanced Technologies SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Plant Advanced Technologies SA

Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include Process PAT Exudactive a sustainable sourcing solution to produce your exclusive, personalized Exudactive; and PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes. Plant Advanced Technologies SA was incorporated in 2005 and is headquartered in …

Full company profile